inclusion criteria: individuals aged 18 or over, regardless of gender; patients hospitalized in moderate to severe stages in line with the ministry of health classification; positive diagnosis for sars-cov-2 by molecular amplification of the virus in rt-pcr diagnosed from a respiratory sample (nasopharynx, oropharyngeal, lower respiratory tract [eg, sputum]) collected <96 hours before randomization; time of onset of symptoms and inclusion ≤ 14 days; internation within 48 hours after inclusion in the study; follow-up availability during the study period; voluntary membership to participate in the study and signing the informed consent form.

inclusion criteria: individuals aged 18 or over, regardless of gender; patients hospitalized in moderate to severe stages in line with the ministry of health classification; positive diagnosis for sars-cov-2 by molecular amplification of the virus in rt-pcr diagnosed from a respiratory sample (nasopharynx, oropharyngeal, lower respiratory tract [eg, sputum]) collected <96 hours before randomization; time of onset of symptoms and inclusion ≤ 14 days; internation within 48 hours after inclusion in the study; follow-up availability during the study period; voluntary membership to participate in the study and signing the informed consent form.

inclusion criteria: 1. individuals aged 18 or over, regardless of gender; 2. patients hospitalized in moderate to severe stages in line with the ministry of health classification; 3. positive diagnosis for sars-cov-2 by molecular amplification of the virus in rt-pcr diagnosed from a respiratory sample (nasopharynx, oropharyngeal, lower respiratory tract [eg, sputum]) collected <96 hours before randomization; 4. time of onset of symptoms and inclusion ≤ 14 days; 5. internation within 48 hours after inclusion in the study; 6. follow-up availability during the study period; 7. voluntary membership to participate in the study and signing the informed consent form.

inclusion criteria: 1. individuals aged 18 or over, regardless of gender; 2. patients hospitalized in moderate to severe stages in line with the ministry of health classification; 3. positive diagnosis for sars-cov-2 by molecular amplification of the virus in rt-pcr diagnosed from a respiratory sample (nasopharynx, oropharyngeal, lower respiratory tract [eg, sputum]) collected <96 hours before randomization; 4. time of onset of symptoms and inclusion ≤ 14 days; 5. internation within 48 hours after inclusion in the study; 6. follow-up availability during the study period; 7. voluntary membership to participate in the study and signing the informed consent form.